Aim: Rare missense variants, which likely account for a substantial portion of the genetic 'dark matter' for a common complex disease, are challenging because the impacts of variants on disease development are difficult to substantiate. This study aimed to examine the impacts of amino acid substitution variants in the POLG1 found in bipolar disorder, as an example and proof of concept, in three different modalities of assessment: in silico predictions, in vitro biochemical assays, and clinical evaluation. We then tested whether deleterious variants in POLG1 contributed to the genetics of bipolar disorder.
Methods:
We searched for variants in the POLG1 gene in 796 Japanese patients with bipolar disorder and 767 controls and comprehensively investigated all 23 identified variants in the three modalities of assessment. POLG1 encodes mitochondrial DNA polymerase and is one of the causative genes for a Mendelian-inheritance mitochondrial disease, which is occasionally accompanied by mood disorders. The healthy control data from the Tohoku Medical Megabank Organization were also employed.
Results: Although the frequency of carriers of deleterious variants varied from one method to another, every assessment achieved the same conclusion that deleterious POLG1 variants were significantly enriched in the variants identified in patients with bipolar disorder compared to those in controls.
Conclusion:
Together with mitochondrial dysfunction in bipolar disorder, the present results B IPOLAR DISORDER (BD) is a chronic and severe mental illness with a lifetime prevalence of 2.1% in the USA and 0.4% in Japan. 1, 2 Despite the strong heritability of BD, the underlying genetic architecture remains largely elusive. 3, 4 Genetic studies exploring common variants have identified several loci associated with BD; however, the odds ratios are not high enough to account for the entire architecture of BD. 5, 6 Targeted resequencing of specific genes and, recently, whole genome and exome sequencings have been exploited to identify rare variants, which may constitute a part of the architecture. 7, 8 In this study, on the strength of the hypothesis of mitochondrial dysfunction in BD 9, 10 and the high comorbidity of mood disorder in patients with mitochondrial diseases, 11, 12 we have focused on the POLG1 gene, which is one of the causative genes for chronic progressive external ophthalmoplegia (CPEO), a Mendelian-inheritance mitochondrial disease (OMIM 157640).
Although CPEO is a very rare disease (e.g., one in approximately 600 000 of the general population in Japan), 13 dozens of mutations have been found mostly in the POLG1 gene in patients with autosomal dominant, autosomal recessive, or sporadic CPEO. 14, 15 POLG1 encodes the catalytic subunit of mitochondrial DNA (mtDNA) polymerase, which is the sole DNA polymerase of mtDNA and is expressed ubiquitously even in postmitotic cells. 16 Thus, mutations in the POLG1 can have pleiotropic effects; CPEO-related mutations cause not only myopathy but also other somatic symptoms and a wide range of neuropsychiatric symptoms, including epilepsy, sensorimotor neuropathy, ataxia, Parkinsonism, and psychiatric diseases, 12, 17 such as major depressive disorder, BD, and panic disorder, but not schizophrenia or autism spectrum disorder.
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More than 60 CPEO-related mutations are currently recorded in the Human DNA Polymerase gamma Mutation Database; 18 however, some of them seem to be ambiguous. For example, Y831C (rs41549716, global minor allele frequency
[MAF] = 0.0063) is listed not only as a CPEOrelated mutation but also as a single nucleotide polymorphism (SNP), raising the question as to whether Y831C is deleterious or not. The Japanese Reference Panel Project (1070 individuals) of the Tohoku Medical Megabank (ToMMo) 19 found that R964C (rs201477273) was the most frequent SNP in the POLG1 (MAF = 0.012), though it has been labeled as susceptible to a nucleoside analog reverse-transcriptase inhibitor. 20 In the era of whole genome and exome sequencings, it is becoming crucial to determine whether identified variants have deleterious impacts or are benign for complex disease studies. There are three different types of approach: a computational prediction, a biochemical method, and in vivo observation of knock-in mice or human subjects carrying certain variants. Each of them has both drawbacks and advantages. Computational prediction can quickly assess a number of variants, but the result is no more than prediction. In addition, it is problematic in practice to select one program out of a dozen in silico prediction programs. 21 An in vitro biochemical method, which is laborious, apparently seems to produce correct results, but it is impossible to mimic the actual physiological condition. In contrast, in vivo observation has high reliability; however, generation of knock-in mice is more lengthy and costly, even if genome-editing technology is available. Human data are difficult to interpret due to individual variability, including genetic and environmental differences. This must lead to the difficulty in assessing the above-mentioned Y831C and R964C variants.
In this study, we examined the impacts of POLG1 variants identified in Japanese subjects on the POLG1 protein function and ideally on vulnerability for BD by the three different modalities of assessment, in silico prediction, biochemical assays, and clinical evaluation, which complementally support each other. We also present here a way to select most appropriate prediction programs for particular genes of interest.
METHODS
All experiments were approved by the Ethics Committees of RIKEN and all participating institutes. All participants gave informed consent and their anonymity was preserved. A detailed description of human subjects and methods, including mutation screening, computational prediction, preparation of recombinant POLG1 and POLG2 proteins, polymerase, processivity, exonuclease assays, and statistics can be found in Appendix S1 in Supporting Information.
RESULTS

Identification of amino acid substitution variants in POLG1
We re-sequenced the entire coding sequence of POLG1 in 796 Japanese patients with BD (645 BD-I, 147 BD-II, and four schizoaffective disorder, bipolar type) and 767 controls. We identified 12 amino acid substitution variants (mutations or polymorphisms) in 23 patients and 15 variants in 26 controls (Table 1 and Fig. 1 ). All were heterozygotes. One control subject carried two variants (S731N and H734R). There was no substantial difference in variant frequency in patients and controls (2.9% vs 3.4%). A similar frequency of POLG1 variants was reported in the ToMMo data (40 variants in 1070 healthy Japanese subjects) ( Table 1) . Apparent lossof-function variants, that is, nonsense or frame-shift variants, were found in one patient (E1046X) and one control (H927fs), and two CPEO-related mutations were found in patients (R562Q in one patient and R574W in two patients). We next investigated the impacts of the POLG1 variants that were identified in patients and controls using in silico prediction programs and in vitro biochemical methods.
In silico prediction: POLG1 variants found in BD are more deleterious POLG1 shares conserved catalytic domains with bacterial DNA polymerase I and bacteriophage T7 DNA polymerase 22 ( Fig. 1) , and the crystal structure of human POLG1 is available. 23 It was highly likely that some prediction algorithms would give more correct predictions for POLG1 variants than others, depending on how the rich information about the POLG1 was dealt with. Thus, we first screened eight prediction algorithms (CADD, 24 CONDEL, 25 FATHMM, 26 MutationAssessor, 27 PANTHER, 28 PolyPhen-2, 29 PROVEAN, 30 and SIFT) 31 to select the best one for POLG1 variants. For this screening analysis, 60 CPEO-related mutations, which were listed in the POLG1 mutation database, 18 were used as deleterious variants, and 19 SNPs, which were in the database 18 or were other variants with MAF > 0.001 in the 1000 Genomes or ToMMo datasets, 19, 32 were used as benign variants (Table S1 ). All eight prediction algorithms successfully output higher deleteriousness scores for the CPEO-related mutations (Fig. 2a) ; in particular, the PROVEAN program performed most effectively and robustly (Pearson r = 0.544, U-test method) (Fig. 2b) . Next, we used PROVEAN to predict the deleteriousness of amino acid substitution variants in patients with BD and in controls. In the analysis, the deleteriousness scores of the apparent loss-of-function variants (H927fs and E1046X) were set to −14, which was the lowest score for any possible variant of the human POLG1 (see Fig. S5a ). It was predicted that POLG1 variants found in patients were significantly more deleterious than either those in controls (P = 0.029) or those in the controls plus ToMMo data (P = 0.026) (Fig. 2c) .
Each prediction program not only output continuous scores of deleteriousness but also classified variants into 'deleterious' or 'benign' by a certain threshold or a cut-off point. We investigated whether the binary classification by in silico prediction confirmed the enrichment of deleterious variants of POLG1 in BD. However, even PROVEAN did not perfectly discriminate between CPEO-related mutations and SNP (Fig. 2a) . The accuracy (Matthews correlation coefficient [MCC]) of the binary classification was 0.395. The PolyPhen-2 program yielded a more accurate result (MCC = 0.554) in the classification test, when the threshold between 'benign' and 'possibly damaging' was used (Fig. 2b) . It was predicted using the program that deleterious (or possibly damaging) variants of POLG1 were more frequent in the variants found in patients with BD than those found in controls plus ToMMo data (P = 0.041; one-tailed Fisher's exact test) (Fig. 2d ).
In vitro assessment: Deleterious POLG1 variants are enriched in BD variants
We analyzed the biochemical consequences of all POLG1 variants identified in the Japanese patients and controls as well as several other variants, such as A467T (the most frequent CPEO mutation), 33 Y955C (the best-studied CPEO mutation), [34] [35] [36] and Y831C (see Introduction section). Mutant POLG1 proteins, including the nonsense and frame-shift variants, were expressed in Sf9 cells and were purified almost to homogeneity using the C-terminal histidine tag. DNA polymerase activity (processivity) and 3 0 ! 5 0 exonuclease activity were examined using a fluorescently labeled oligonucleotide-single-stranded DNA hybrid. Exonuclease-deficient POLG1 variants, which contained D198A+E200A mutations as well as the respective variants, were also prepared to assess exactly the polymerase activity. 37 These enzyme activities were examined in the presence of POLG2 (Fig. 3a,b, and Fig. S1a) , the dimer of which binds to POLG1 protein at the linker region 33 ( Fig. 1) and also in the absence of POLG2 (Figs S1b, S2b, and S3b). Functional alterations of these variants, including lack of protein expression and loss or decrease of processivity, polymerase, or exonuclease activities, are summarized in Table 2 . There was a significant correlation between the three activities of each variant (exonuclease vs processivity, Spearman's rank correlation coefficient ρ = 0.871, P = 1.9 × 10 −10
; processivity vs polymerase, ρ = 0.811, P = 3.1 × 10
−8
). The polymerase activity and processivity of POLG1 were more robust in the presence of POLG2 than those in the absence of POLG2 (Figs S1 and S3) and the exonuclease activity was not subject to POLG2 (Fig. S2) . The presence of POLG2 did not have a marked influence on impact of variants; severely impaired activities of several POLG1 mutants, including mutants of CPEOrelated mutations (A467T, R562Q, R574W, and Y955C), were not ameliorated even in the presence of POLG2 (Table 2) .
Based on the lowest enzymatic activity of each variant in the presence of POLG2, we provided an overall evaluation (a zero-to-three scale) to each of the POLG1 variants (Table 2 ) and compared the evaluation scores of variants found in patients with those in controls. We found that biochemically less active variants were significantly enriched in the variants identified in patients compared to those in controls (P = 0.039, U-test) (Fig. 3c) . Because several variants recently identified in the ToMMo controls were not examined in the in vitro assays, we excluded the ToMMo data from the analysis.
We compared the biochemical activities of POLG1 variants with the in silico predictions, PROVEAN score, and PolyPhen-2 binary classification. Both the programs significantly predicted the biochemical impacts of POLG1 variants (PROVEAN, P = 0.0083, Spearman's rank correlation; PolyPhen-2, P = 0.014, U-test) (Fig. S4) , which supported the validity of the application of these prediction programs to the POLG1 variant analysis (Fig. 2c,d ). Either the biochemical analysis or in silico predictions demonstrated that most of the POLG1 variants located in the linker domain and the polymerase domain were likely deleterious (Table 2 and Fig. S5 ). These POLG1 variants were severely deprived of both the exonuclease and polymerase activities, in contrast to variants in the exonuclease domain, which affected only the exonuclease activity (Table 2) .
Evaluation based on reports in CPEO patients: CPEO-related POLG1 mutations are found only in BD In addition to the in silico and in vitro assessments, we estimated the in vivo consequences of POLG1 variants based on the reported clinical data. 18 As stated Human POLG1 protein contains the exonuclease and polymerase domains that possess 3 0 ! 5 0 exonuclease and DNA polymerase activities, respectively. 17, 22 The domains share considerable sequence and 3-D structure homologies with bacterial DNA polymerase I and bacteriophage T7 DNA polymerase. 17, 22, 23 The linker region locating in the polymerase domain (or roughly between the two domains) interacts with and binds to POLG2 dimer. 23 Human POLG1 protein harbors a polyglutamine tract in the Introduction, patients with CPEO frequently harbor mutations in the POLG1 gene; these CPEOrelated mutations are apparently deleterious in vivo. We found two CPEO-related mutations, R562Q and R574W, in three patients with BD (Table 1) . Both the mutations were classified as deleterious by the in silico and in vitro methods ( Table 2 ). The R562Q mutation, which was found in a patient with BD-I, rapid cycling, had been identified in a CPEO patient with myopathy 38 (Table S2 ). The R574W mutation, which was found in two unrelated patients with BD-I, had been identified in a CPEO patient with dysphagia and myopathy.
14 None of CPEO-related mutations that were listed in the POLG1 mutation database 18 were found in healthy controls or the ToMMo data. Although the frequency of patients carrying CPEO-related mutations was very low (0.38%), CPEO-related mutations were significantly more frequent in patients with BD compared to controls plus ToMMo data (P = 0.028, Fisher's exact test).
DISCUSSION
In the present study, we thoroughly characterized the 23 POLG1 variants identified in Japanese patients with BD and controls by using three approaches of analysis. Every analysis achieved the same conclusion that deleterious variants were enriched in the variants identified in patients with BD (Figs 2c,d and 3c) . Together with the established observations, namely, mitochondrial dysfunction in BD 9, 10 and high frequent comorbidity of BD in mitochondrial diseases, 11, 12 the present results suggest deleterious variants in the POLG1 gene as a risk for BD.
A great number of rare variants have recently been identified with the development of sequencing and have been assessed principally using in silico prediction programs. It is difficult to select one program out of several prediction algorithms with distinct characteristics. In this study, we selected the best algorithms for POLG1 variant prediction in an unbiased manner (Fig. 2a) and assessed variants we identified using the best algorithms. This procedure will be effective when variants of particular genes are assessed in silico. Computational algorithms predict deleteriousness of variants based on various kinds of information, such as phylogenetic similarity among homologs (orthologs and paralogs), 3-D structures, and epidemiological, clinical, and genetic characteristics of the variants. The width and depth of the information greatly vary among genes and how to handle the information also varies among algorithms, and as a result, variants in certain genes can be predicted more correctly by certain algorithms. In the case of POLG1 variants, although in silico predictions were significantly correlated with the in vitro assessment (Fig. S4) , the prediction algorithms likely gave more deleterious scores than the biochemical assessment (Table 2 and Fig. S4 ). We cannot tell whether the in silico prediction algorithms overevaluated the impacts of POLG1 variants or the biochemical assessment underevaluated them, because the in silico method is still immature and also because in vitro experiments cannot mimic the physiological condition and cannot test as-yetunrecognized activities or functions. Considering that both the methods robustly detected deleterious impacts of CPEO-related mutations (Table 2) , however, we could argue that the combined assessment with three different modalities, in silico, in vitro, and in vivo (or clinical data survey), was favorable and fruitful. We found two CPEO-related mutations, R562Q and R574W, in three patients with BD. The R562Q had been identified as a heterozygous mutation in a sporadic patient with CPEO 38 and the R574W was found as a compound heterozygote mutation. 14 Although CPEO is a Mendelian genetic disease, the inheritance pattern of POLG1 mutations is not simple; some mutations represent a dominant trait or a recessive trait of CPEO, and sometimes also lead to other diseases, such as Alpers syndrome, encephalopathy, epilepsy (and probably BD). The complex genetics involving the POLG1 gene may occur for not only CPEO and the other POLG1-related diseases but also for BD. The R562Q and Exo (-)  WT  Q43R  L112F  W113G  N134K  R177Q  Q238R  P241L  G268A  H277L  S332F  P412S  P412L   Exonuclease domain   S462L  A467T  R562Q  S731N  H734R  K751R  Y831C  R866W  H932Q  Y955C  R964C  S998L  T1199I A1217V
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(a) Polymerase activity No POLG1  WT  Q43R  L112F  W113G  N134K  P163S  R177Q  A219D  Q238R  P241L  G268A  H277L  S332F  P412S  P412L  S462L  A467T  R562Q  R574W  S731N  H734R  K751R  Y831C  R866W  H932Q  Y955C  R964C  S998L  T1199I R574W found in patients with BD were not tightly segregated in each family (Table S2 ). In addition, the frequency of carriers of deleterious variants of POLG1 in BD was low: CPEO-related mutations, 0.38%; deleterious variants biochemically defined, 2.3%; variants predicted as deleterious, 2.4%. However, CPEO-related mutations of POLG1 were significantly enriched in patients with BD ( Table 2 ), suggesting that they confer a risk for BD. In contrast, genome-wide association studies on BD have not detected any significant signals in the POLG1 region, 5, 6 which indicates that there is no common functional polymorphism that is associated with BD. We assume that BD has genetic architectures constructed with common SNPs, copy number variants, and rare deleterious variants.
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Given that deleterious variants of POLG1 constitute a part of the genetic architecture of BD, the brain circuit architecture is then of much interest. We have recently reported a transgenic mouse line, in which an exonuclease-deficient mutant of POLG1 (D198A in human POLG1) is expressed exclusively in the forebrain neurons, spontaneously exhibiting recurrent mood episodes. 39 The mutant mice and post-mortem brains of CPEO patients with mood symptoms highlighted the paraventricular nucleus of thalamus (PVT), and PVT-specific inhibition of neural transmission triggered depression-like behavioral change in mice. 39 The PVT plays a prominent role in stress and fear responses [40] [41] [42] and also participates in circadian behaviors 43 that are relevant to BD. 44 It seems reasonable to conjecture a converging path from deleterious variants in POLG1 into the final common pathway of BD as follows: deleterious POLG1 variants, then resultant mtDNA deletions and mitochondrial dysfunction in the PVT, and then impaired neural circuit(s) involving PVT, which would be close to the final common pathway. Further studies will be needed to elucidate the pathophysiology of BD.
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